Highlights

  • CSL has entered an exclusive agreement to co-develop and co-promote lixudebart, an investigational monoclonal antibody targeting rare kidney and liver diseases.
  • CSL will make an upfront payment of US$355 million, while additional commercial milestone payments could reach US$1.2 billion.
  • The company will fully fund the ongoing Phase 2 RENAL trial, a planned Phase 3 trial in AAV-RPGN, and Phase 2 studies in FSGS and PSC.
  • If commercialised, global profits from lixudebart will be shared 55% to CSL and 45% to its development partner.

CSL Limited (ASX:CSL) is a global biotechnology company with operations spanning therapies for serious and rare diseases. CSL shares were quoted at A$176.92 on 5 October 2026. Its latest announcement adds lixudebart to the company’s development pipeline through an exclusive co-development and co-promotion agreement focused on rare kidney and liver disorders.

Exclusive Agreement Adds Rare Disease Asset

On 5 October 2026, CSL announced that it had entered an agreement with Alentis Therapeutics to jointly develop and commercialise lixudebart. The therapy is being investigated as a potential first-in-class treatment for patients with rare kidney and liver diseases.

Lixudebart is currently being evaluated in an ongoing Phase 2 trial in patients with ANCA-associated vasculitis with rapidly progressive glomerulonephritis, or AAV-RPGN. The condition is a rare autoimmune disease that can result in rapid deterioration of kidney function and, in severe cases, end-stage renal disease.

The drug is designed to target both inflammation and fibrosis, two biological processes associated with longer-term organ injury.

US$355 Million Upfront Payment

Under the agreement, CSL will make an initial payment of US$355 million. The development partner is also eligible to receive up to a further US$1.2 billion in commercial milestone payments.

In addition to those payments, CSL will fully fund the completion of the ongoing Phase 2 RENAL study and a planned Phase 3 trial in AAV-RPGN. CSL will also fund Phase 2 trials in focal segmental glomerulosclerosis, or FSGS, and primary sclerosing cholangitis, or PSC, together with other supporting development work.

The announcement does not provide a timetable for potential regulatory submissions or commercial launch.

Profit Sharing Set at 55% for CSL

If lixudebart reaches commercialisation, global profits will be shared between the parties, with CSL receiving 55% and Alentis receiving 45%.

The structure therefore combines a sizeable upfront payment with milestone-based consideration and a continuing profit-sharing arrangement. The commercial outcome remains dependent on successful clinical development and subsequent regulatory approval.

The release does not include updated revenue, profit or cash-flow guidance for CSL, so there is no new year-on-year financial increase or decline to quantify from this announcement alone.

Development Program Extends Beyond AAV-RPGN

CSL and its partner also plan to assess lixudebart in FSGS, a chronic kidney disease, and PSC, a chronic liver disease. According to the announcement, there is currently no available therapy for PSC.

Lixudebart is an investigational monoclonal antibody that targets exposed claudin-1, which the announcement identifies as a driver of inflammatory and fibrotic signalling pathways across several organs.

An interim analysis from 26 patients in the ongoing Phase 2 RENAL trial showed improvement in kidney function based on eGFR and proteinuria at 24 weeks. In a separate Phase 1b liver fibrosis study involving 41 patients with advanced F3/F4 fibrosis, the therapy showed improved liver function at six weeks.

These remain early and mid-stage clinical findings rather than completed pivotal trial results.

Nephrology Becomes a Larger Development Focus

The agreement is consistent with CSL’s stated intention to build a broader nephrology franchise. The company indicated that the collaboration also forms part of its strategy of using external partnerships to expand its pipeline.

The potential scope of the asset extends across multiple fibrotic and inflammatory diseases, although the current development plans identified in the announcement are centred on AAV-RPGN, FSGS and PSC.

Lixudebart has also received Orphan Drug designation from the U.S. Food and Drug Administration for idiopathic pulmonary fibrosis, although that indication is not part of the principal development plans outlined in this agreement.

Closing Perspective

CSL’s agreement for lixudebart expands its rare-disease development pipeline while committing significant Capital to clinical development. The US$355 million upfront payment is accompanied by potential milestone obligations of up to US$1.2 billion, while CSL will also fund several clinical trials. The commercial opportunity remains dependent on clinical and regulatory progress, with the asset still undergoing Phase 2 evaluation in its lead kidney-disease indication.